[
  {
    "ts": null,
    "headline": "Why Regeneron's Price May Soon Break Out",
    "summary": "Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.",
    "url": "https://finnhub.io/api/news?id=d5af37c15f7937cb7659c25bbaefc15e6d819270430ea1e30992e3c141a5a315",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739742843,
      "headline": "Why Regeneron's Price May Soon Break Out",
      "id": 132742765,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.",
      "url": "https://finnhub.io/api/news?id=d5af37c15f7937cb7659c25bbaefc15e6d819270430ea1e30992e3c141a5a315"
    }
  },
  {
    "ts": null,
    "headline": "Olema Pharmaceuticals: Interesting But Undifferentiated Data",
    "summary": "Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=4a7cf445d2a71b004fcf3d687404551917a19476c8f9c672e4ac275bd3a50481",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739739069,
      "headline": "Olema Pharmaceuticals: Interesting But Undifferentiated Data",
      "id": 132742554,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=4a7cf445d2a71b004fcf3d687404551917a19476c8f9c672e4ac275bd3a50481"
    }
  },
  {
    "ts": null,
    "headline": "Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills",
    "summary": "Investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. Read more to see my picks.",
    "url": "https://finnhub.io/api/news?id=40d6274b76bf8bb588d5084af586a46cf76363d8060f9776f673aa56c28c7b1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739692419,
      "headline": "Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills",
      "id": 132739332,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1204857576/image_1204857576.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. Read more to see my picks.",
      "url": "https://finnhub.io/api/news?id=40d6274b76bf8bb588d5084af586a46cf76363d8060f9776f673aa56c28c7b1d"
    }
  }
]